Primary information |
---|
sequence ID | Seq_3246 |
Peptide sequence | GTCSGCNCNGHAS |
CancerPDF_ID | CancerPDF_ID3428, CancerPDF_ID3549, |
PMID | 27026199,27026199 |
Protein Name | Basement membrane-specific heparan sulfate proteoglycan core protein,Basement membrane-specific heparan sulfate proteoglycan core protein |
UniprotKB Entry Name | HSPG2_HUMAN,PGBM_HUMAN |
Fluid | Urine,Urine |
M/Z | NA,NA |
Charge | NA,NA |
Mass (in Da) | NA,NA |
fdr | 1210.37,1210.37 |
Profiling Technique | "CE-MS, Micro-TOF-MS","CE-MS, Micro-TOF-MS" |
Peptide Identification technique | MS-MS,MS-MS |
Quantification Technique | NA,NA |
Labelled/Label Free | Label Free,Label Free |
FDR | NA,NA |
CancerPDF_ID | CancerPDF_ID3428, CancerPDF_ID3549, |
p-Value | less than 0.05,3.10E-04 |
Software | Proteome Discoverer 1.2,Proteome Discoverer 1.2 |
Length | 13,13 |
Cancer Type | Bladder cancer,Bladder cancer |
Database | Uniprot Human non-redundant Database,Uniprot Human non-redundant Database |
Modification | NA,NA |
Number of Patients | 451 for training (341 patients and 110 normal) and 270 for testing(168 primary UBC patients and 102 normal controls);, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
Regulation | Differentially expressed between primary UBC and normal individual,Differentially expressed between recurrence of UBC vs recurrence control |
Validation | Independent Validation,Independent Validation |
Sensitivity | For testing dataset 91%,For testing dataset 88% |
Specificity | For testing dataset 68%,For testing dataset 51% |
Accuracy | For testing dataset 76%,NA |
Peptide Atlas | NA |
IEDB | |